key: cord-0899941-i7sl5q89
authors: Hasanpourghadi, Mohadeseh; Novikov, Mikhail; Ertl, Hildegund C.J.
title: COVID-19 Vaccines Based on Adenovirus Vectors
date: 2021-03-14
journal: Trends Biochem Sci
DOI: 10.1016/j.tibs.2021.03.002
sha: b1d624464c106b6d2cd993a81ebe360233a9c274
doc_id: 899941
cord_uid: i7sl5q89

nan

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2021 Published by Elsevier.

Mohadeseh Hasanpourghadi 1 , Mikhail Novikov 1 , and Hildegund CJ Ertl 1 * Wistar Institute 3601 Spruce Street Philadelphia, PA, USA *Correspondence: ertl@wistar.org (Ertl, H CJ) Summary (for Figure 1 ) Adenovirus (Ad) vectors are produced from molecular clones (MC) of the Ad genome [1] . E1 and E3 domains are deleted; removal of E1 prevents virus replication. The genome is cloned into a plasmid vector. Infected cells provide viral RNA, e.g., spike of SARS-CoV-2. Spike sequences are amplified and cloned into a shuttle vector from where the expression cassette is excised and inserted into an Ad MC. Ad MC transfection of E1 + helper cells rescues the vaccine, which is expanded, tested, and ready for GMP production and clinical trials.

(for Figure 2 ) Ad vaccines infect CAR + cells. They produce spike protein, which induces antibody-secreting plasma cells and memory B cells. Antigen-presenting cells take up and process spike to bind to MHC antigens for stimulation of CD4 + or CD8 + T cells, which help activation of other cells or have antiviral functions. Ad vaccines induce virus neutralizing antibodies (VNAs) to Ad, which inhibit Ad vaccines; VNAs to different Ad serotypes have no effect [2] .

Neutralizing antibodies to common human serotypes of Ad viruses reduce vaccine immunogenicity [7] . Neutralizing antibodies to the Ad vector induced by the 1 st immunization reduce immune responses to a 2 nd immunization with the same Ad vector. Antigen encoded by the Ad vaccine persists for a period of time, which delays transition of lymphocytes into memory, potentially requiring extended intervals between two vaccine doses [8] .

An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector

Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase

/2 studies from Russia

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers

Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human-or chimpanzee-derived adenovirus vectors

Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines